$80.00
Thymosin alpha 1 (Ta1) is an N terminally acetylated 28 amino acid peptide first isolated from calf thymus tissue in 1977. Its international nonproprietary name is thymalfasin. It is sold as a prescription medicine under the brand name Zadaxin in some countries and is authorised in Italy, but the FDA has stated that Ta1 is not approved in the United States, Japan or Europe outside Italy, and Health Canada’s Drug Product Database lists no product containing it. The lyophilized material on this page is a research chemical and is not Zadaxin.
Thymosin alpha 1 (Ta1) is a small acidic peptide that was isolated from calf thymus tissue and sequenced by Goldstein and colleagues in 1977, as one of the components of the preparation then called thymosin fraction 5. It is 28 amino acids long and is acetylated at the N terminus. The synthetic peptide carries the international nonproprietary name thymalfasin. Ta1 is used in immunology research as a reference peptide when measuring T cell differentiation markers and cytokine readouts.
No single high affinity receptor has been established for Ta1. Published mechanistic work has reported signalling that depends on Toll like receptor 9 in dendritic cells, and this remains an active research question rather than a settled pathway.
Ta1 is marketed as a prescription medicine under the brand name Zadaxin (SciClone Pharmaceuticals). In a December 2024 review presented to its Pharmacy Compounding Advisory Committee, the FDA stated that Ta1 is not approved in the United States, Japan or Europe with the exception of Italy, and that it is not recognized in the European or Japanese Pharmacopoeias. The FDA also noted that claims of approval across the Asia Pacific region, Latin America, Eastern Europe and the Middle East could not be independently verified, and that it has approved no drug product containing Ta1. The European Medicines Agency granted thymalfasin an EU orphan designation for hepatocellular carcinoma on 30 July 2002; an orphan designation is not a marketing authorisation.
Health Canada’s Drug Product Database contains no drug product with thymalfasin or thymosin alpha 1 as an active ingredient, so it is not authorized for sale as a drug in Canada. The material offered on this page is a laboratory research chemical. It is not Zadaxin, it is not a licensed or authorized medicine in Canada, and it is not supplied for any medical purpose.
Reported areas of study, with the evidence level stated:
Every batch of Thymosin Alpha-1 10mg undergoes:
HPLC and mass spectrometry characterize chemical purity and identity. They do not measure biological activity, and no potency testing is performed or implied.
For laboratory research use only. Not for human or veterinary use.
Further reading